Business Description
Twist Bioscience Corp
NAICS : 339112
SIC : 8099
ISIN : US90184D1000
Total Employee Number:
979Description
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.78 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -0.83 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 15.46 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 18.6 | |||||
3-Year EBITDA Growth Rate | 22 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year FCF Growth Rate | 33 | |||||
3-Year Book Growth Rate | -17.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.94 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90.48 | |||||
9-Day RSI | 80.72 | |||||
14-Day RSI | 74.21 | |||||
3-1 Month Momentum % | 73.45 | |||||
6-1 Month Momentum % | 114.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.67 | |||||
Quick Ratio | 2.38 | |||||
Cash Ratio | 1.39 | |||||
Days Inventory | 54.85 | |||||
Days Sales Outstanding | 48.38 | |||||
Days Payable | 23.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -0.14 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.97 | |||||
Operating Margin % | -31.95 | |||||
Net Margin % | -31.66 | |||||
EBITDA Margin % | -26.07 | |||||
FCF Margin % | -21.53 | |||||
OCF Margin % | -12.24 | |||||
ROE % | -29.62 | |||||
ROA % | -20.89 | |||||
ROIC % | -34.35 | |||||
3-Year ROIIC % | -195.95 | |||||
ROC (Joel Greenblatt) % | -72.15 | |||||
ROCE % | -24.88 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 15.52 | |||||
PB Ratio | 15.34 | |||||
Price-to-Tangible-Book | 19.49 | |||||
EV-to-EBIT | -49.05 | |||||
EV-to-Forward-EBIT | -59.41 | |||||
EV-to-EBITDA | -60.11 | |||||
EV-to-Revenue | 15.67 | |||||
EV-to-Forward-Revenue | 12.72 | |||||
EV-to-FCF | -72.59 | |||||
Price-to-GF-Value | 2.09 | |||||
| Price-to-Net-Current-Asset-Value | 72.18 | |||||
Earnings Yield (Greenblatt) % | -2.04 | |||||
FCF Yield % | -1.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Twist Bioscience Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 371.432 | ||
| EPS (TTM) (€) | -1.91 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 74.21 | ||
| 14-Day ATR (€) | 2.397466 | ||
| 20-Day SMA (€) | 81.544 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 19.5 - 101.05 | ||
| Shares Outstanding (Mil) | 62.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Twist Bioscience Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Twist Bioscience Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2027 | 2027-02-05 07:00 | In 183 days | ||
| First quarter earnings conference call for 2027 | 2027-02-02 08:00 | In 180 days | ||
| First quarter earnings results for 2027 | 2027-02-02 | In 179 days | ||
| Annual report for 2026 | 2026-11-17 | In 102 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-11-13 08:00 | In 99 days | ||
| Fourth quarter earnings results for 2026 | 2026-11-13 | In 98 days | ||
| Third quarter earnings conference call for 2026 | 2026-08-03 08:00 | 75.90 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-08-03 | 75.90 (+0.00%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-02 10:00 | 57.74 (+0.91%) | ||
| Analyst meeting for 2026 | 2026-05-21 11:00 | 44.27 (+4.12%) |
Show
Entries
Twist Bioscience Corp Frequently Asked Questions
What is Twist Bioscience Corp(MIL:1TWST)'s stock price today?
The current price of MIL:1TWST is €97.44. The 52 week high of MIL:1TWST is €101.05 and 52 week low is €19.50.
When is next earnings date of Twist Bioscience Corp(MIL:1TWST)?
The next earnings date of Twist Bioscience Corp(MIL:1TWST) is 2026-11-13 Est..
Does Twist Bioscience Corp(MIL:1TWST) pay dividends? If so, how much?
Twist Bioscience Corp(MIL:1TWST) does not pay dividend.
Press Release
Articles on Twist Bioscience Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers